Related Experiment Video
Updated: Jun 28, 2026

Surgical Swine Model of Chronic Cardiac Ischemia Treated by Off-Pump Coronary Artery Bypass Graft Surgery
Published on: March 27, 2018
Recent insights into coronary collateral circulation
1Second Department of Internal Medicine, Toyama Medical and Pharmaceutical University, Japan.
Insights
Coronary collaterals protect the heart during myocardial infarction by reducing infarct size and improving function. Heparin may enhance therapeutic angiogenesis for ischemic heart disease.
Area of Science:
- Cardiology
- Vascular Biology
- Regenerative Medicine
Background:
- The role of coronary collaterals in human heart disease has long been debated.
- Collateral vessels are crucial for supplying blood to ischemic heart tissue.
- Understanding collateral development and function is key to treating heart disease.
Purpose of the Study:
- To investigate the functional significance of coronary collaterals in myocardial infarction.
- To explore the mechanisms of collateral development and the role of growth factors.
- To evaluate the therapeutic potential of heparin in promoting angiogenesis for coronary artery disease.
Main Methods:
- Correlating collateral visualization during acute myocardial infarction with clinical outcomes (infarct size, ventricular function).
- Examining the cellular and molecular mechanisms of collateral growth in response to ischemia.
- Clinical trial assessing the efficacy of heparin combined with exercise in patients with coronary artery disease.
Main Results:
- Visualized coronary collaterals were associated with smaller infarcts, less aneurysm formation, and better ventricular function.
- Myocardial ischemia stimulates collateral development through DNA replication and cell mitosis.
- Heparin potentiates growth factors, promoting angiogenesis and improving exercise capacity in patients.
Conclusions:
- Coronary collaterals play a significant protective role in ischemic heart disease.
- Angiogenesis, stimulated by growth factors and potentially potentiated by heparin, offers a therapeutic strategy.
- Further research into neovascularization could lead to new treatments for ischemic heart disease.
Abstract:
The functional significance of coronary collaterals in humans has been debated for many years. Correlations have now been made between the anatomic appearance of coronary collateral vessels visualized at the time of intracoronary thrombolytic therapy during the acute phase of myocardial infarction and the creatine kinase time--activity curve, infarct size, and aneurysm formation. These studies demonstrate a protective role of collaterals in hearts with coronary obstructive disease, showing smaller infarcts, less aneurysm formation, and improved ventricular function compared with patients in whom collaterals were not visualized. There is ample evidence that collaterals respond to myocardial ischemia by opening preexistent channels. When the cardiac myocyte is rendered ischemic, collaterals develop actively by growth with DNA replication and mitosis of endothelial and smooth muscle cells. Heparin-binding growth factors are present in the heart, but their biological activity is quiescent under normal physiological conditions. Once ischemia develops, these factors are activated and become available for receptor occupation, which may initiate angiogenesis after exposure to exogenous heparin. This characteristic of heparin to potentiate the mitogenic activity of acidic fibroblast growth factor has recently been used in the clinical setting as a possible therapeutic modality in patients with coronary artery disease. Patients performing 20 rounds of exercise serially after receiving intravenous injection of heparin showed significantly greater increases in exercise capacity and improvement of clinical symptoms compared with the control group who performed the same exercise without heparin. Further study of neovascularization may lead to a new therapeutic strategy for ischemic heart disease.(ABSTRACT TRUNCATED AT 250 WORDS)
Related Concept Videos
Mitral Stenosis III: Medical Management
Aortic Regurgitation I: Introduction
Aortic Regurgitation III: Medical Management
Heart Failure VI: Adjunct Therapies
Cardiomyopathy II: Dilated Cardiomyopathy
Cardiomyopathy V: Interprofessional Care

